OncoSec Medical Incorporated (NASDAQ:ONCS) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.33.

Several equities research analysts recently weighed in on the company. ValuEngine raised OncoSec Medical from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the company a “buy” rating in a report on Saturday, June 3rd. Dawson James reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Thursday, July 6th. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a report on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the company a “buy” rating in a report on Monday, June 12th.

TRADEMARK VIOLATION NOTICE: “Brokerages Set OncoSec Medical Incorporated (ONCS) Price Target at $5.33” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/brokerages-set-oncosec-medical-incorporated-oncs-price-target-at-5-33/1516483.html.

OncoSec Medical (NASDAQ ONCS) traded up 5.61% on Friday, reaching $0.94. 80,794 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $1.04 and its 200 day moving average is $1.16. The stock’s market capitalization is $19.90 million. OncoSec Medical has a 1-year low of $0.88 and a 1-year high of $2.08.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. Analysts expect that OncoSec Medical will post ($1.02) EPS for the current year.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.